S&P Futures
4,151.50 +9.75 (+0.24%) Dow Futures
32,861.00 +69.00 (+0.21%) Nasdaq Futures
13,214.00 +30.75 (+0.23%) Russell 2000 Futures
1,946.50 +5.40 (+0.28%) Crude Oil
90.86 +0.10 (+0.11%) Gold
1,802.40 -2.80 (-0.16%)
Cellectis S.A. (CLLS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.4600 |
| Open | 3.7000 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 800 |
| Day's Range | 3.5450 - 3.7000 |
| 52 Week Range | 2.3000 - 15.5000 |
| Volume | |
| Avg. Volume | 140,829 |
| Market Cap | 166.041M |
| Beta (5Y Monthly) | 2.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.9520 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.38 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CLLS
Related Research
- Cellectis S.A.Analyst Report: Intellia Therapeutics, Inc.Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.RatingFair ValueEconomic Moat3 days agoMorningstar
- Zacks
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
- GlobeNewswire
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022
IND clearance received from FDA for UCART20x22 for the treatment of Non-Hodgkin LymphomaCellectis unveiled novel immune-evasive universal allogeneic CAR T-cell in Nature Communications; awarded oral presentation at ASGCT in MayMr. Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D. appointed as Directors of Cellectis’ Board of DirectorsCash position1 of $135 million as of June 30, 2022 Conference call scheduled for 8AM ET/2PM CET on August 5, 2022 NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) --
- GlobeNewswire
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies
UCART20x22 is Cellectis’ first allogeneic dual CAR T, targeting CD20 and CD22 simultaneously UCART20x22 is Cellectis’ first product candidate fully designed, developed and manufactured in-house Phase 1/2a clinical trial NatHaLi-01 expected to begin in second half of the year NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and
